Scorpio® Cruciate Retaining (CR) Outcomes Study
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the design and functional performance of the Scorpio® Cruciate Retaining (CR) Total Knee System.
| Condition | Intervention |
|---|---|
|
Arthropathy of Knee |
Device: Scorpio® CR Total Knee System |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open Label, Post-market, Non-randomized, Multi-center Study of the Outcomes of the Scorpio® Cruciate Retaining (CR) Total Knee System |
- Evaluate Component Design Effect on Functional Knee Society Score and Radiographic Findings. [ Time Frame: 15 years ] [ Designated as safety issue: No ]This study was terminated prior to the protocol defined 15 year endpoint. As such, final outcome measures cannot be posted.
- Evaluate Complication Rate. [ Time Frame: 15 years ] [ Designated as safety issue: Yes ]This study was terminated prior to the protocol defined 15 year endpoint. As such, final outcome measures cannot be posted.
| Enrollment: | 215 |
| Study Start Date: | June 2001 |
| Estimated Primary Completion Date: | July 2018 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Scorpio® CR Total Knee System
Scorpio® CR Total Knee System Study Device
|
Device: Scorpio® CR Total Knee System
All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
Other Name: Scorpio® Cruciate Retaining (CR) Total Knee System
|
Detailed Description:
The study design is a prospective, multi-center clinical trial. The Scorpio® Cruciate Retaining (CR) Total Knee System is to be implanted for evaluation in this study. This device system is commercially available and is intended for cemented use.
The study group will consist of a maximum of 265 cases, requiring primary total knee replacement, and diagnosed with non-inflammatory arthritis. All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella. Subjects receiving bilateral total knee replacements will represent two cases. Study participants will be recruited from 5 institutions.
Subjects will be evaluated preoperatively and at follow-up intervals of 7 wks (± 2 wks), 3 months (± 3 weeks), 6 months (optional visit), 12 months (± 2 months) and annually thereafter (± 2 months). Each subject will be followed for 15 years post-implantation.
The objectives of this study are to:
- Evaluate the effect of system component design on functional performance.
- Evaluate the effect of system component design by comparing postoperative functional and radiographic findings with preoperative.
- Evaluate complications and the rates in which they occur.
Eligibility| Ages Eligible for Study: | 21 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The subject is a male or non-pregnant female between the ages of 21-80.
- The subject requires a primary cemented total knee replacement.
- The subject has a diagnosis of osteoarthritis (OA), traumatic arthritis (TA), or avascular necrosis (AVN).
- The subject has intact collateral ligaments.
- The subject has signed the IRB approved, study specific Informed Patient Consent Form.
- The subject is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.
Exclusion Criteria:
- Patient has inflammatory arthritis.
- The subject is morbidly obese, >60% over ideal body weight for frame and height.
- The subject has a history of total or unicompartmental reconstruction of the affected joint.
- Patient has had a high tibial osteotomy or femoral osteotomy.
- The subject has a neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device.
- The subject has a systemic or metabolic disorder leading to progressive bone deterioration.
- The subject is immunologically suppressed, or receiving steroids in excess of normal physiological requirements.
- The subject's bone stock is compromised by disease or infection which cannot provide adequate support and/or fixation to the prosthesis.
- The subject has had a knee fusion to the affected joint.
- The subject has an active or suspected latent infection in or about the knee joint.
- The subject is a prisoner.
- The subject is pregnant.
Contacts and Locations| United States, Arkansas | |
| Foundation for Musculoskeletal Research and Education | |
| Little Rock, Arkansas, United States, 72205 | |
| United States, Indiana | |
| Orthopaedic Research Foundation, Inc. | |
| Indianapolis, Indiana, United States, 46237 | |
| United States, Kentucky | |
| Jewish Physician Group | |
| Louisville, Kentucky, United States, 40202 | |
| United States, Michigan | |
| Dearborn Orthopaedics | |
| Dearborn, Michigan, United States, 48124 | |
| United States, New York | |
| Beth Israel Medical Center | |
| New York, New York, United States, 10021 | |
| Study Chair: | C. Lowry Barnes, MD | Foundation for Musculoskeletal Research and Education |
| Principal Investigator: | Lawrence Morawa, MD | Dearborn Orthopaedics |
| Principal Investigator: | Arthur Malkani, MD | Jewish Physician Group |
| Principal Investigator: | Frank Kolisek, MD | Orthopaedic Research Foundation, Inc. |
| Principal Investigator: | Steven Harwin, MD | Beth Israel Medical Center |
More Information
No publications provided
| Responsible Party: | Stryker Orthopaedics |
| ClinicalTrials.gov Identifier: | NCT00965146 History of Changes |
| Other Study ID Numbers: | 48 |
| Study First Received: | August 11, 2009 |
| Results First Received: | November 9, 2012 |
| Last Updated: | April 8, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Stryker Orthopaedics:
|
Osteoarthritis, traumatic arthritis, avascular necrosis |
Additional relevant MeSH terms:
|
Joint Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on June 18, 2013